It is well-established that C26 cachexia alters the plasma levels of several soluble factors including TNFα, IL-1β and IL-6 which can accelerate the activity of key proteolytic pathways involved in the development of muscle weakness [23, 24]. The gene discussed is IL6; the disease is Cachexia.